encorafenib + Binimetinib + Cetuximab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
BRAF V600E-mutant Metastatic Colorectal Cancer
Conditions
BRAF V600E-mutant Metastatic Colorectal Cancer
Trial Timeline
Jan 17, 2019 → Apr 27, 2023
NCT ID
NCT03693170About encorafenib + Binimetinib + Cetuximab
encorafenib + Binimetinib + Cetuximab is a phase 2 stage product being developed by Ono Pharmaceutical for BRAF V600E-mutant Metastatic Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03693170. Target conditions include BRAF V600E-mutant Metastatic Colorectal Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03693170 | Phase 2 | Completed |
Competing Products
13 competing products in BRAF V600E-mutant Metastatic Colorectal Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PLX3397 + vemurafenib | Daiichi Sankyo | Phase 1 | 33 |
| TMZ + E7016 | Eisai | Phase 2 | 52 |
| Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-Fluorouracil | Ono Pharmaceutical | Phase 3 | 77 |
| Encorafenib + Cetuximab + FOLFIRI | Merck | Phase 2 | 52 |
| Tafinlar/Mekinist | Novartis | Pre-clinical | 23 |
| BKM120 Combined with Vemurafenib (PLX4032) | Novartis | Phase 1/2 | 41 |
| Dabrafenib + LTT462 + Trametinib + LXH254 + TNO155 + Spartalizumab + Tislelizumab | Novartis | Phase 1 | 33 |
| Cobimetinib + Atezolizumab + Pembrolizumab | Roche | Phase 3 | 77 |
| LGX818 + MEK162 + LEE011 | Pfizer | Phase 1/2 | 40 |
| MEK162 | Pfizer | Phase 2 | 51 |
| Encorafenib + Binimetinib + cemiplimab+fianlimab | Regeneron Pharmaceuticals | Phase 2 | 51 |
| Plixorafenib + Cobicistat 150 MG [Tybost] | Brain Biotech | Phase 1 | 25 |
| Dabrafenib + Trametinib + Hydroxychloroquine | Brain Biotech | Phase 1/2 | 33 |